Expertise in
3
conditions

Yajin J. Chen

No. 107 Yanjiang West Road, 
Guangzhou, CN 
Expertise in
3
conditions
No. 107 Yanjiang West Road, 
Guangzhou, CN 

Overview

Yajin Chen practices practicing medicine in Guangzhou, China.

Chen is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Liver Cancer, Cholangiocarcinoma (Bile Duct Cancer), Zellweger Syndrome, Hepato-Pancreato-Biliary Surgery, and Hepatectomy.

They are actively involved in clinical research, co-authoring 89 peer reviewed articles and participating in 2 clinical trials.

Locations

No. 107 Yanjiang West Road, Guangzhou, 510120, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets
Study Phase: Phase 3
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
View 1 Less Clinical Trial

89 Total Publications

The role and evaluation of ALPPS in surgical treatment of hepatocellular carcinoma in the era of conversion therapy
The role and evaluation of ALPPS in surgical treatment of hepatocellular carcinoma in the era of conversion therapy
Journal: Zhonghua wai ke za zhi [Chinese journal of surgery]
Published: August 30, 2026

Frequently Asked Questions about Yajin J. Chen

Is Yajin J. Chen a top-rated expert for Liver Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Yajin J. Chen is classified as an Distinguished expert for Liver Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yajin J. Chen participate in research or clinical trials?

Yes. Yajin J. Chen has published 89 articles and abstracts on conditions like Liver Cancer. You can view a list of Yajin J. Chen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chen's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile